PDUVA VII commitment letter: RWE, rare diseases see renewed attention

PDUVA VII commitment letter: RWE, rare diseases see renewed attention

Submitted by admin on August 23, 2021 - 11:20pm
Source: 
RAPS.org
News Tags: 
FDA
regulatory
PDUFA VII
RWE
real world evidence
Headline: 
PDUVA VII commitment letter: RWE, rare diseases see renewed attention
snippet: 

The US Food and Drug Administration (FDA) on Monday released the commitment letter outlining performance goals and procedures for the upcoming reauthorization of the Prescription Drug User Fee Amendments for FYs 2023-2027 (PDUFA VII).

Do Not Allow Advertisers to Use My Personal information